查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1566934

癌症诊断市场中的人工智慧：按组件、类型和最终用户划分：2024-2033 年全球机会分析和产业预测

Artificial Intelligence In Cancer Diagnostics Market By Component , By Type By End user : Global Opportunity Analysis and Industry Forecast, 2024-2033
出版日期: | 出版商: Allied Market Research | 英文 280 Pages | 商品交期: 2-3个工作天内

价格
简介目录

2023年，癌症诊断领域的人工智慧市场价值为2亿美元，预计2024年至2033年复合年增长率为23.6%，到2033年将达到17亿美元。

人工智慧正在帮助医疗保健专业人员检测、分析和治疗各种类型的癌症，从而改变癌症诊断。透过利用先进的演算法和机器学习技术，人工智慧可以提高诊断过程的准确性、速度和效率，为患者和医疗保健专业人员带来显着的好处。人工智慧有潜力透过赋予医疗保健工作者权力和简化诊断过程来改善患者的治疗结果并推动对抗癌症的斗争。

全球癌症诊断人工智慧市场的成长是由全球各类癌症盛行率的惊人成长以及对先进诊断工具来管理和治疗不断增加的病例的需求所推动的。根据世界卫生组织 (WHO) 估计，2022 年将有 2,000 万名癌症患者和 970 万人死亡。此外，对癌症早期检测和製定个人化治疗计划的需求不断增长，推动了对人工智慧改善患者治疗效果的需求。此外，与癌症诊断中的人工智慧相关的多种好处也对市场成长做出了重大贡献。例如，人工智慧不仅可以透过支援放射科医生和病理学家来帮助减轻医疗系统的负担，而且人工智慧主导的诊断可以透过简化流程和减少错误来改善医疗保健。此外，公众和专业人士对医疗保健领域人工智慧的认识和接受程度不断提高，也大大推动了市场的成长。然而，实施人工智慧所需的高额初始投资，如技术取得、培训和维护，是全球市场的主要阻碍因素。将人工智慧系统与现有的医疗基础设施和电子健康记录整合非常复杂，并且会产生额外的成本，从而限制了市场的成长。此外，人工智慧和医疗保健领域专家的缺乏限制了人工智慧解决方案的采用和开发。相反，将人工智慧纳入远端医疗平台以提供远距离诊断服务预计将为预测期内全球市场的扩张提供利润丰厚的机会。据美国国家癌症美国称，在大流行期间进行了约 25,500 次远端医疗，其中莫菲特癌症中心的临床医生进行了超过 11,600次远距医疗访问，莫菲特癌症中心是美国癌症研究所指定的位于佛罗里达州的虚拟癌症中心。这样，远端医疗服务中的人工智慧就可以对慢性病患者进行持续监测。此外，使用人工智慧分析血液样本提供了非侵入性诊断选择，预计将为市场成长开闢新的途径。

癌症诊断人工智慧的全球市场按组件、类型、最终用户和地区进行细分。按组成部分，市场分为软体、服务和硬体。依类型分为乳癌、肺癌、摄护腺癌等。依最终用户划分，该细分市场可分为医院、诊断中心等。按地区划分，对北美、欧洲、亚太地区和拉丁美洲地区市场进行了分析。

主要发现

从组成部分来看，到 2023 年，软体领域将在癌症诊断市场的人工智慧领域占据主导地位。

按类型划分，预计到 2033 年乳癌细分市场将引领市场。

按最终用户划分，医院领域在 2023 年呈现最高成长。

按地区划分，北美很可能在 2023 年成为主要收益来源，并在预测期内主导市场。

可以自订此报告（需要额外的费用和时间表）

  • 监管指引
  • 根据客户兴趣加入公司简介
  • 按国家或地区进行的附加分析 – 市场规模和预测
  • 公司简介的扩充列表
  • 历史市场资料
  • SWOT分析

目录

第一章简介

第 2 章执行摘要

第三章 市场状况

  • 市场定义和范围
  • 主要发现
    • 主要投资机会
    • 关键成功策略
  • 波特五力分析
  • 市场动态
    • 促进因素
    • 抑制因素
    • 机会

第四章癌症诊断中的人工智慧市场：按组成部分

  • 市场概况
  • 软体
  • 服务
  • 硬体

第五章癌症诊断中的人工智慧市场：按类型

  • 市场概况
  • 乳癌
  • 肺癌
  • 摄护腺癌
  • 其他的

第六章癌症诊断中的人工智慧市场：按最终用户划分

  • 市场概况
  • 医院
  • 诊断中心
  • 其他的

第七章癌症诊断中的人工智慧市场：按地区

  • 市场概况
  • 北美洲
    • 主要市场趋势和机会
    • 美国癌症诊断的人工智慧市场
    • 加拿大癌症诊断的人工智慧市场
    • 墨西哥癌症诊断中的人工智慧市场
  • 欧洲
    • 主要市场趋势和机会
    • 法国癌症诊断中的人工智慧市场
    • 德国癌症诊断中的人工智慧市场
    • 义大利癌症诊断的人工智慧市场
    • 西班牙癌症诊断中的人工智慧市场
    • 英国癌症诊断中的人工智慧市场
    • 癌症诊断人工智慧的其他欧洲国家市场
  • 亚太地区
    • 主要市场趋势和机会
    • 中国癌症诊断的人工智慧市场
    • 日本癌症诊断中的人工智慧市场
    • 印度癌症诊断中的人工智慧市场
    • 韩国癌症诊断中的人工智慧市场
    • 澳洲癌症诊断中的人工智慧市场
    • 其他亚太地区癌症诊断人工智慧市场
  • 拉丁美洲/中东/非洲
    • 主要市场趋势和机会
    • 巴西癌症诊断中的人工智慧市场
    • 南非癌症诊断中的人工智慧市场
    • 沙乌地阿拉伯癌症诊断中的人工智慧市场
    • 拉丁美洲、中东和非洲癌症诊断人工智慧的其他市场

第八章 竞争格局

  • 介绍
  • 关键成功策略
  • 10家主要企业产品图谱
  • 竞争对手仪表板
  • 竞争热图
  • 主要企业定位（2023年）

第九章 公司简介

  • Siemens Healthineers AG
  • Nanox Imaging LTD
  • Riverain Technologies
  • Vuno, Inc.
  • Aidoc
  • Neural Analytics
  • Imagen Technologies
  • Digital Diagnostics
  • GE Healthcare
  • AliveCor Inc.
简介目录
Product Code: A323966

The artificial intelligence in cancer diagnostics market was valued at $0.2 billion in 2023, and is projected to reach $1.7 billion by 2033, growing at a CAGR of 23.6% from 2024 to 2033.

Artificial intelligence is transforming cancer diagnostics by helping healthcare professionals to detect, analyze, and treat various types of cancer. By leveraging advanced algorithms and machine learning techniques, artificial intelligence enhances the accuracy, speed, and efficiency of diagnostic processes, offering significant benefits to both patients and medical practitioners. Artificial intelligence holds the potential to improve patient outcomes and advance the fight against cancer by enhancing the capabilities of medical professionals and streamlining diagnostic processes.

The growth of the global artificial intelligence in cancer diagnostics market is majorly driven by alarming increase in prevalence of various types of cancer worldwide, which necessitates advanced diagnostic tools to manage and treat the growing number of cases. According to the estimates of the World Health Organization, 20 million cancer cases and 9.7 million deaths were reported in 2022. Moreover, rise in need for early cancer detection and development of personalized treatment plans fosters the need for artificial intelligence to improve patient outcomes. In addition, multiple benefits associated with artificial intelligence in cancer diagnostics significantly contributes toward the market growth. For instance, artificial intelligence helps to alleviate the burden on healthcare systems by supporting radiologists and pathologists as well as artificial intelligence-driven diagnostics can reduce healthcare costs by streamlining processes and minimizing errors. Furthermore, growing awareness and acceptance of artificial intelligence in healthcare among the public and professionals is considerably propelling the market growth. However, high initial investment required for implementation of artificial intelligence, including technology acquisition, training, and maintenance acts as a key deterrent factor of the global market. Integrating artificial intelligence systems with existing healthcare infrastructure and electronic health records is complex and incurs additional cost, thereby restraining the growth of the market. Moreover, dearth of professionals with expertise in both artificial intelligence and healthcare limits the adoption and development of artificial intelligence solutions. On the contrary, incorporating artificial intelligence with telemedicine platforms to provide remote diagnostic services is expected to offer remunerative opportunities for the expansion of the global market during the forecast period. According to the National Cancer Institute, approximately 25,500 telehealth visits were conducted during the pandemic, among which over 11,600 were adult cancer patients who received virtual consultations from clinicians at the Moffitt Cancer Center, a National Cancer Institute-designated Comprehensive Cancer Center located in Florida. Thus, artificial intelligence in telehealth services will enable continuous monitoring of patients with chronic conditions. Furthermore, using artificial intelligence to analyze blood samples offers a non-invasive diagnostic option, which is anticipated to open new avenues for the growth of the market.

The global artificial intelligence in cancer diagnostics market is segmented into component, type, end user, and region. By component, the market is categorized into software, services, and hardware. On the basis of type, it is classified into breast cancer, lung cancer, prostate cancer, and others. Depending on end user, it is fragmented into hospitals, diagnostic centers, and others. Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Key Findings

By component, the software segment dominated the artificial intelligence in cancer diagnostics market in 2023.

On the basis of type, the breast cancer segment is expected to lead the market by 2033.

Depending on end user, the hospital segment exhibited the highest growth in 2023.

Region wise, North America was the major revenue generator in 2023, and is likely to dominate the market during the forecast period.

Competition Analysis

Competitive analysis and profiles of the major players in the global artificial intelligence in cancer diagnostics market include Siemens Healthineers AG, Nanox Imaging LTD, Riverain Technologies, Vuno, Inc., Aidoc, Neural Analytics, Imagen Technologies, Digital Diagnostics, GE Healthcare, and AliveCor Inc. These major players have adopted various key development strategies such as business expansion, new product launches, and partnerships to strengthen their foothold in the competitive market.

Additional benefits you will get with this purchase are:

  • Quarterly Update and* (only available with a corporate license, on listed price)
  • 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
  • Free Upcoming Version on the Purchase of Five and Enterprise User License.
  • 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
  • 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
  • Free data Pack on the Five and Enterprise User License. (Excel version of the report)
  • Free Updated report if the report is 6-12 months old or older.
  • 24-hour priority response*
  • Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

  • Regulatory Guidelines
  • Additional company profiles with specific to client's interest
  • Additional country or region analysis- market size and forecast
  • Expanded list for Company Profiles
  • Historic market data
  • SWOT Analysis

Key Market Segments

By Component

  • Software
  • Services
  • Hardware

By Type

  • Breast cancer
  • Lung cancer
  • Prostate cancer
  • Others

By End User

  • Hospitals
  • Diagnostic centers
  • Others

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • France
    • Germany
    • Italy
    • Spain
    • UK
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • South Africa
    • Saudi Arabia
    • Rest of LAMEA

Key Market Players:

    • Siemens Healthineers AG
    • Nanox Imaging LTD
    • Riverain Technologies
    • Vuno, Inc.
    • Aidoc
    • Neural Analytics
    • Imagen Technologies
    • Digital Diagnostics
    • GE Healthcare
    • AliveCor Inc.

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report Description
  • 1.2. Key Market Segments
  • 1.3. Key Benefits
  • 1.4. Research Methodology
    • 1.4.1. Primary Research
    • 1.4.2. Secondary Research
    • 1.4.3. Analyst Tools and Models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO Perspective

CHAPTER 3: MARKET LANDSCAPE

  • 3.1. Market Definition and Scope
  • 3.2. Key Findings
    • 3.2.1. Top Investment Pockets
    • 3.2.2. Top Winning Strategies
  • 3.3. Porter's Five Forces Analysis
    • 3.3.1. Bargaining Power of Suppliers
    • 3.3.2. Threat of New Entrants
    • 3.3.3. Threat of Substitutes
    • 3.3.4. Competitive Rivalry
    • 3.3.5. Bargaining Power among Buyers
  • 3.4. Market Dynamics
    • 3.4.1. Drivers
    • 3.4.2. Restraints
    • 3.4.3. Opportunities

CHAPTER 4: ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS MARKET, BY COMPONENT

  • 4.1. Market Overview
    • 4.1.1 Market Size and Forecast, By Component
  • 4.2. Software
    • 4.2.1. Key Market Trends, Growth Factors and Opportunities
    • 4.2.2. Market Size and Forecast, By Region
    • 4.2.3. Market Share Analysis, By Country
  • 4.3. Services
    • 4.3.1. Key Market Trends, Growth Factors and Opportunities
    • 4.3.2. Market Size and Forecast, By Region
    • 4.3.3. Market Share Analysis, By Country
  • 4.4. Hardware
    • 4.4.1. Key Market Trends, Growth Factors and Opportunities
    • 4.4.2. Market Size and Forecast, By Region
    • 4.4.3. Market Share Analysis, By Country

CHAPTER 5: ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS MARKET, BY TYPE

  • 5.1. Market Overview
    • 5.1.1 Market Size and Forecast, By Type
  • 5.2. Breast Cancer
    • 5.2.1. Key Market Trends, Growth Factors and Opportunities
    • 5.2.2. Market Size and Forecast, By Region
    • 5.2.3. Market Share Analysis, By Country
  • 5.3. Lung Cancer
    • 5.3.1. Key Market Trends, Growth Factors and Opportunities
    • 5.3.2. Market Size and Forecast, By Region
    • 5.3.3. Market Share Analysis, By Country
  • 5.4. Prostate Cancer
    • 5.4.1. Key Market Trends, Growth Factors and Opportunities
    • 5.4.2. Market Size and Forecast, By Region
    • 5.4.3. Market Share Analysis, By Country
  • 5.5. Others
    • 5.5.1. Key Market Trends, Growth Factors and Opportunities
    • 5.5.2. Market Size and Forecast, By Region
    • 5.5.3. Market Share Analysis, By Country

CHAPTER 6: ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS MARKET, BY END USER

  • 6.1. Market Overview
    • 6.1.1 Market Size and Forecast, By End User
  • 6.2. Hospitals
    • 6.2.1. Key Market Trends, Growth Factors and Opportunities
    • 6.2.2. Market Size and Forecast, By Region
    • 6.2.3. Market Share Analysis, By Country
  • 6.3. Diagnostic Centers
    • 6.3.1. Key Market Trends, Growth Factors and Opportunities
    • 6.3.2. Market Size and Forecast, By Region
    • 6.3.3. Market Share Analysis, By Country
  • 6.4. Others
    • 6.4.1. Key Market Trends, Growth Factors and Opportunities
    • 6.4.2. Market Size and Forecast, By Region
    • 6.4.3. Market Share Analysis, By Country

CHAPTER 7: ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS MARKET, BY REGION

  • 7.1. Market Overview
    • 7.1.1 Market Size and Forecast, By Region
  • 7.2. North America
    • 7.2.1. Key Market Trends and Opportunities
    • 7.2.2. Market Size and Forecast, By Component
    • 7.2.3. Market Size and Forecast, By Type
    • 7.2.4. Market Size and Forecast, By End User
    • 7.2.5. Market Size and Forecast, By Country
    • 7.2.6. U.S. Artificial Intelligence In Cancer Diagnostics Market
      • 7.2.6.1. Market Size and Forecast, By Component
      • 7.2.6.2. Market Size and Forecast, By Type
      • 7.2.6.3. Market Size and Forecast, By End User
    • 7.2.7. Canada Artificial Intelligence In Cancer Diagnostics Market
      • 7.2.7.1. Market Size and Forecast, By Component
      • 7.2.7.2. Market Size and Forecast, By Type
      • 7.2.7.3. Market Size and Forecast, By End User
    • 7.2.8. Mexico Artificial Intelligence In Cancer Diagnostics Market
      • 7.2.8.1. Market Size and Forecast, By Component
      • 7.2.8.2. Market Size and Forecast, By Type
      • 7.2.8.3. Market Size and Forecast, By End User
  • 7.3. Europe
    • 7.3.1. Key Market Trends and Opportunities
    • 7.3.2. Market Size and Forecast, By Component
    • 7.3.3. Market Size and Forecast, By Type
    • 7.3.4. Market Size and Forecast, By End User
    • 7.3.5. Market Size and Forecast, By Country
    • 7.3.6. France Artificial Intelligence In Cancer Diagnostics Market
      • 7.3.6.1. Market Size and Forecast, By Component
      • 7.3.6.2. Market Size and Forecast, By Type
      • 7.3.6.3. Market Size and Forecast, By End User
    • 7.3.7. Germany Artificial Intelligence In Cancer Diagnostics Market
      • 7.3.7.1. Market Size and Forecast, By Component
      • 7.3.7.2. Market Size and Forecast, By Type
      • 7.3.7.3. Market Size and Forecast, By End User
    • 7.3.8. Italy Artificial Intelligence In Cancer Diagnostics Market
      • 7.3.8.1. Market Size and Forecast, By Component
      • 7.3.8.2. Market Size and Forecast, By Type
      • 7.3.8.3. Market Size and Forecast, By End User
    • 7.3.9. Spain Artificial Intelligence In Cancer Diagnostics Market
      • 7.3.9.1. Market Size and Forecast, By Component
      • 7.3.9.2. Market Size and Forecast, By Type
      • 7.3.9.3. Market Size and Forecast, By End User
    • 7.3.10. UK Artificial Intelligence In Cancer Diagnostics Market
      • 7.3.10.1. Market Size and Forecast, By Component
      • 7.3.10.2. Market Size and Forecast, By Type
      • 7.3.10.3. Market Size and Forecast, By End User
    • 7.3.11. Rest of Europe Artificial Intelligence In Cancer Diagnostics Market
      • 7.3.11.1. Market Size and Forecast, By Component
      • 7.3.11.2. Market Size and Forecast, By Type
      • 7.3.11.3. Market Size and Forecast, By End User
  • 7.4. Asia-Pacific
    • 7.4.1. Key Market Trends and Opportunities
    • 7.4.2. Market Size and Forecast, By Component
    • 7.4.3. Market Size and Forecast, By Type
    • 7.4.4. Market Size and Forecast, By End User
    • 7.4.5. Market Size and Forecast, By Country
    • 7.4.6. China Artificial Intelligence In Cancer Diagnostics Market
      • 7.4.6.1. Market Size and Forecast, By Component
      • 7.4.6.2. Market Size and Forecast, By Type
      • 7.4.6.3. Market Size and Forecast, By End User
    • 7.4.7. Japan Artificial Intelligence In Cancer Diagnostics Market
      • 7.4.7.1. Market Size and Forecast, By Component
      • 7.4.7.2. Market Size and Forecast, By Type
      • 7.4.7.3. Market Size and Forecast, By End User
    • 7.4.8. India Artificial Intelligence In Cancer Diagnostics Market
      • 7.4.8.1. Market Size and Forecast, By Component
      • 7.4.8.2. Market Size and Forecast, By Type
      • 7.4.8.3. Market Size and Forecast, By End User
    • 7.4.9. South Korea Artificial Intelligence In Cancer Diagnostics Market
      • 7.4.9.1. Market Size and Forecast, By Component
      • 7.4.9.2. Market Size and Forecast, By Type
      • 7.4.9.3. Market Size and Forecast, By End User
    • 7.4.10. Australia Artificial Intelligence In Cancer Diagnostics Market
      • 7.4.10.1. Market Size and Forecast, By Component
      • 7.4.10.2. Market Size and Forecast, By Type
      • 7.4.10.3. Market Size and Forecast, By End User
    • 7.4.11. Rest of Asia-Pacific Artificial Intelligence In Cancer Diagnostics Market
      • 7.4.11.1. Market Size and Forecast, By Component
      • 7.4.11.2. Market Size and Forecast, By Type
      • 7.4.11.3. Market Size and Forecast, By End User
  • 7.5. LAMEA
    • 7.5.1. Key Market Trends and Opportunities
    • 7.5.2. Market Size and Forecast, By Component
    • 7.5.3. Market Size and Forecast, By Type
    • 7.5.4. Market Size and Forecast, By End User
    • 7.5.5. Market Size and Forecast, By Country
    • 7.5.6. Brazil Artificial Intelligence In Cancer Diagnostics Market
      • 7.5.6.1. Market Size and Forecast, By Component
      • 7.5.6.2. Market Size and Forecast, By Type
      • 7.5.6.3. Market Size and Forecast, By End User
    • 7.5.7. South Africa Artificial Intelligence In Cancer Diagnostics Market
      • 7.5.7.1. Market Size and Forecast, By Component
      • 7.5.7.2. Market Size and Forecast, By Type
      • 7.5.7.3. Market Size and Forecast, By End User
    • 7.5.8. Saudi Arabia Artificial Intelligence In Cancer Diagnostics Market
      • 7.5.8.1. Market Size and Forecast, By Component
      • 7.5.8.2. Market Size and Forecast, By Type
      • 7.5.8.3. Market Size and Forecast, By End User
    • 7.5.9. Rest of LAMEA Artificial Intelligence In Cancer Diagnostics Market
      • 7.5.9.1. Market Size and Forecast, By Component
      • 7.5.9.2. Market Size and Forecast, By Type
      • 7.5.9.3. Market Size and Forecast, By End User

CHAPTER 8: COMPETITIVE LANDSCAPE

  • 8.1. Introduction
  • 8.2. Top Winning Strategies
  • 8.3. Product Mapping of Top 10 Player
  • 8.4. Competitive Dashboard
  • 8.5. Competitive Heatmap
  • 8.6. Top Player Positioning, 2023

CHAPTER 9: COMPANY PROFILES

  • 9.1. Siemens Healthineers AG
    • 9.1.1. Company Overview
    • 9.1.2. Key Executives
    • 9.1.3. Company Snapshot
    • 9.1.4. Operating Business Segments
    • 9.1.5. Product Portfolio
    • 9.1.6. Business Performance
    • 9.1.7. Key Strategic Moves and Developments
  • 9.2. Nanox Imaging LTD
    • 9.2.1. Company Overview
    • 9.2.2. Key Executives
    • 9.2.3. Company Snapshot
    • 9.2.4. Operating Business Segments
    • 9.2.5. Product Portfolio
    • 9.2.6. Business Performance
    • 9.2.7. Key Strategic Moves and Developments
  • 9.3. Riverain Technologies
    • 9.3.1. Company Overview
    • 9.3.2. Key Executives
    • 9.3.3. Company Snapshot
    • 9.3.4. Operating Business Segments
    • 9.3.5. Product Portfolio
    • 9.3.6. Business Performance
    • 9.3.7. Key Strategic Moves and Developments
  • 9.4. Vuno, Inc.
    • 9.4.1. Company Overview
    • 9.4.2. Key Executives
    • 9.4.3. Company Snapshot
    • 9.4.4. Operating Business Segments
    • 9.4.5. Product Portfolio
    • 9.4.6. Business Performance
    • 9.4.7. Key Strategic Moves and Developments
  • 9.5. Aidoc
    • 9.5.1. Company Overview
    • 9.5.2. Key Executives
    • 9.5.3. Company Snapshot
    • 9.5.4. Operating Business Segments
    • 9.5.5. Product Portfolio
    • 9.5.6. Business Performance
    • 9.5.7. Key Strategic Moves and Developments
  • 9.6. Neural Analytics
    • 9.6.1. Company Overview
    • 9.6.2. Key Executives
    • 9.6.3. Company Snapshot
    • 9.6.4. Operating Business Segments
    • 9.6.5. Product Portfolio
    • 9.6.6. Business Performance
    • 9.6.7. Key Strategic Moves and Developments
  • 9.7. Imagen Technologies
    • 9.7.1. Company Overview
    • 9.7.2. Key Executives
    • 9.7.3. Company Snapshot
    • 9.7.4. Operating Business Segments
    • 9.7.5. Product Portfolio
    • 9.7.6. Business Performance
    • 9.7.7. Key Strategic Moves and Developments
  • 9.8. Digital Diagnostics
    • 9.8.1. Company Overview
    • 9.8.2. Key Executives
    • 9.8.3. Company Snapshot
    • 9.8.4. Operating Business Segments
    • 9.8.5. Product Portfolio
    • 9.8.6. Business Performance
    • 9.8.7. Key Strategic Moves and Developments
  • 9.9. GE Healthcare
    • 9.9.1. Company Overview
    • 9.9.2. Key Executives
    • 9.9.3. Company Snapshot
    • 9.9.4. Operating Business Segments
    • 9.9.5. Product Portfolio
    • 9.9.6. Business Performance
    • 9.9.7. Key Strategic Moves and Developments
  • 9.10. AliveCor Inc.
    • 9.10.1. Company Overview
    • 9.10.2. Key Executives
    • 9.10.3. Company Snapshot
    • 9.10.4. Operating Business Segments
    • 9.10.5. Product Portfolio
    • 9.10.6. Business Performance
    • 9.10.7. Key Strategic Moves and Developments